Scientists have made a groundbreaking discovery in the field of cancer diagnosis.
They have developed a blood test, known as HrC, that can detect specific markers indicating changes in the behavior of stem cells that are a precursor to cancer mutations.
The test has been proven to be 100% accurate in identifying signs of cancer up to a year before tumors have even formed.
Even the control group of patients who were believed to be cancer-free were accurately detected by the test.
The biopsy technique, co-developed by Mumbai-based biotech firm Epigeneres and Singapore-based diagnostic company Tzar Labs, could be the biggest cancer breakthrough in decades.
The first trial of 1,000 patients, published in Stem Cell Reviews and Reports, found that the blood sample passed through “next generation” gene sequencing machinery not only picked up early signals of the disease before cancer cells formed, but also identified cancer types and stages once they had developed.
Plans are being made for trials across leading universities and hospitals in the UK, including Imperial College, Manchester University, and Cardiff University.
Dr. Sherif Raouf, a leading consultant gastrointestinal cancer specialist, said that detecting cancer at the earliest stage is the holy grail of cancer medicine and that this blood test could be a game-changer.
Ashish Tripathi, the CEO of Tzar Labs, said that this screening method has been shown to detect all types of cancer early, from a simple blood test, even before tumors have formed.
It is the first prognostic or predictive test for cancer in the world.
Article updated 2 months ago. Content is written and modified by multiple authors.
